港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降血液制品业务受多因素影响

智通财经02-02

智通财经APP获悉，华润医药(03320)跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。消息面上，华润医药发布公告，于2026年1月30日，华润博雅生物公布其截至2025年12月31日止年度的业绩预告，其公告截至2025年12月31日止年度归属于华润博雅生物股东的净利润预计约人民币1.05亿元至人民币1.365亿元(上年同期净利润约人民币3.97亿元)、扣除非经常性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608713839?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-02 11:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608713839","market":"fut","top_or_hot":-1,"title":"港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，华润医药(03320)跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。消息面上，华润医药发布公告，于2026年1月30日，华润博雅生物公布其截至2025年12月31日止年度的业绩预告，其公告截至2025年12月31日止年度归属于华润博雅生物股东的净利润预计约人民币1.05亿元至人民币1.365亿元(上年同期净利润约人民币3.97亿元)、扣除非经常性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400441.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 11:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1400441.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，华润医药(03320)跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。消息面上，华润医药发布公告，于2026年1月30日，华润博雅生物公布其截至2025年12月31日止年度的业绩预告，其公告截至2025年12月31日止年度归属于华润博雅生物股东的净利润预计约人民币1.05亿元至人民币1.365亿元(上年同期净利润约人民币3.97亿元)、扣除非经常性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400441.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1400441.html","article_id":"2608713839","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608713839","pubTimestamp":1770003478,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，华润医药跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。公告称，华润博雅生物的血液制品业务受到扩大集采、DRG/DIP改革、医疗保险费用控制及重点监管合理用药等因素影响，导致临床处方减少以及需求下降，与此同时，市场竞争持续加剧，导致报告期内华润博雅生物血液制品业务的毛利率同比下降。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300294":"博雅生物","BK0046":"生物疫苗","BK4585":"ETF&股票定投概念","VT":"世界全股市ETF-Vanguard","BK0239":"医药制造","03320":"华润医药","BK4588":"碎股","BK1191":"制药","BK1570":"华润系","BK0197":"中小创蓝筹"},"translate_title":"Changes in Hong Kong stocks | China Resources Pharmaceutical (03320) fell nearly 3%. China Resources Boya Biotech expects annual net profit attributable to its parent company to drop sharply year-on-year. The blood products business is affected by multiple factors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300294":1.5,"03320":1.5,"VT":1.5},"content_text":"智通财经APP获悉，华润医药(03320)跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。消息面上，华润医药发布公告，于2026年1月30日，华润博雅生物公布其截至2025年12月31日止年度的业绩预告，其公告截至2025年12月31日止年度归属于华润博雅生物股东的净利润预计约人民币1.05亿元至人民币1.365亿元(上年同期净利润约人民币3.97亿元)、扣除非经常性损益后归属于华润博雅生物股东的净亏损预计约人民币750万元至人民币1500万元(上年同期净利润约人民币3.02亿元)(华润博雅生物业绩预告)。公告称，华润博雅生物的血液制品业务受到扩大集采、DRG/DIP改革、医疗保险费用控制及重点监管合理用药等因素影响，导致临床处方减少以及需求下降，与此同时，市场竞争持续加剧，导致报告期内华润博雅生物血液制品业务的毛利率同比下降。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608713839","isCrawlerRequest":true}

港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响

精彩评论

港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降血液制品业务受多因素影响